Loading stock data…
KIDS
$18.49+0.26 (+1.43%)
After Hours$18.49+0.00 (+0.00%)· Last close Jun 9
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
OrthoPediatrics Corp. in the Healthcare sector is trading at $18.49. Wall Street consensus targets $24.67 (9 analysts), implying a +33.4% move over the next 12 months. The stock is currently 22% below its 52-week high of $23.70, remaining 4.5% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +33.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$18.49
Potential Downside
0%
Whystock Fair Value$18.49
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-11.71%
Volume
Today's trading volume
96,314
Recent News
Why The OrthoPediatrics (KIDS) Narrative Is Evolving Without A New Price Target
OrthoPediatrics enters this update cycle with no change to its existing price target, giving you a steady reference point as the story develops. Even without a fresh valuation reset or new analyst commentary to dissect, the lack of movement can still tell you something about how expectations are holding. Read on to see how to track this kind of quiet update and follow the evolving narrative around the stock. Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other...
How The OrthoPediatrics (KIDS) Story Is Shifting As Analysts Reassess Growth And Valuation
The blended fair value estimate for OrthoPediatrics has shifted from US$24.00 to about US$24.67 per share, reflecting a modest adjustment to the stock’s perceived potential. This move sits alongside a split in Street views, where some analysts have raised targets into the low US$20s while others have trimmed their numbers, leaving the overall narrative more finely balanced. As you read on, you will see how this evolving analyst debate can help you frame your own view on the stock. Analyst...
Is the Selloff in OrthoPediatrics Corp. (KIDS) Creating a Buying Opportunity?
Minot Light Capital Partners, an investment management company, released its “Capital Appreciation Fund” Q1 2026 Investor Letter. A copy of the letter can be downloaded here. The fund declined by 2.7% in the first quarter of 2026 due to a sharp macro-driven sector rotation following geopolitical tensions, which triggered inflation fears and rising interest rate […]
OrthoPediatrics Corp (KIDS) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ...
OrthoPediatrics Corp (KIDS) reports a 13% revenue increase and raises 2026 guidance, while navigating weather impacts and cautious product launch timelines.
OrthoPediatrics (KIDS) Q1 2026 Earnings Transcript
During the call today, management will also discuss certain non-GAAP financial measures, which are supplemental measures of performance. For each non-GAAP financial measure referenced on this call, the company has included a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures in its first quarter earnings release. Please note that the non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for OrthoPediatrics Corp. financial results prepared in accordance with GAAP.